SL: Insider Intelligence Trade Alert 4/6/23

Buy Alert: Beyond Air Inc. (NYSE: XAIR)

Price at alert: \$6.64

Buy Limit: \$7.35

Stop Limit: \$5.30

Hey, it's Alex here with your next Insider Intelligence Trade Alert.

This week, we're looking at **Beyond Air Inc.** The company manufactures a variety of machines that convert regular air to condensed nitric oxide.

Nitric oxide is used for a variety of lung ailments, ranging from COPD, pneumonia, and bronchitis, to neonatal applications. The best way to think of Beyond Air is as a medical device company.

One of their products, the LungFit PH, has been approved by the FDA to treat pulmonary hypertension in newborns. The company currently has another product going through FDA trials to see if it can successfully treat nontuberculous mycobacteria, viral community-acquired pneumonia, and other lung ailments.

They also have a subdivision called Beyond Cancer, where they're trialing a novel use of targeted nitric oxide to treat certain solid tumors.

The stock has been fairly range-bound over the past few months:




But will the price breakout soon?


Judging by the amount of insider activity taking place, it seems like something could be happening soon.

In March alone, a total of 9 insiders have scooped up shares. This is a great example of cluster buying, where multiple insiders buy in around the same time.

You have COO Michael Gaul who's bought 9,000 total shares between two different transactions (the most recent is pictured.)



CEO and Chairman of the Board Steven Lisi has bought 60,000 shares worth about \$362k.



Chief Business Officer Amir Avniel bought 1,000 shares:



And the various board members bought the rest.

What could be causing so much buying activity? Well, here's a list of XAIR's various products and their pipeline status:



The most likely catalyst would be the cardiac surgery pipeline for the LungFit PH product. As the graphic shows, there is a PMA submission that will be filed in the first half of 2023. PMA stands for Premarket Approval. So, the company submitting it has to show the FDA that the device has been shown to be safe and effective for the end user.

During this application process, the company must submit any clinical trial data it might have. So, if I had to guess, I would think that there has been positive clinical trial data for using the LungFit PH in a cardiac surgery setting. And the insiders think that the device is likely to pass the PMA process.

Considering that the LungFit PH has already been approved for commercial use in other applications, it seems a good bet that it would have some benefit for cardiac surgery care.

So, considering all that, we're adding **Beyond Air Inc.** to the Insider Intelligence Model Portfolio.

To access past Insider Intelligence alerts, our model portfolio and everything else, simply go to wealthpin.com/II

To your wealth,

Alex Reid Founder, Insider Intelligence